Keywords
Prognosis
Hepatocellular carcinoma
Niger
How to Cite
Abstract
Introduction :
Hepatocellular carcinoma (HCC) is a common complication of chronic liver disease. Its weight is enormous in the context of the high endemicity of the hepatitis B virus. The objective of this work was to describe the epidemiological and prognostic aspects of hepatocellular carcinoma. Materials and Methods: This was a cross-sectional study with retrospective data collection from January 01, 2021 to December 31, 2023 on the records of patients followed on an outpatient basis and/or hospitalized in the Hepato-Gastroenterology Department (HGE) of the Zinder National Hospital (HNZ) for HCC.
Results :
there were 514 cases including 275 cases of chronic liver disease, among which there were 113 cases of hepatocellular carcinoma, i.e. 21.98% of reasons for hospitalization. The mean age was 42.02±16.26 years with a predominance of men (sex ratio at 1.33). The reasons for hospitalization were deterioration in general condition (71.75%), abdominal pain (32.82%), abdominal mass (12.98%), hepatic encephalopathy (12.98%) and gastrointestinal bleeding (12.98%). Patients were classified BCLC C/D in 100% (n=131). The alfa-fetoprotein level was greater than 500 ng/ml in 86.26% (n=113). Viral hepatitis B and its markers accounted for 87.78% (n=115) of the etiologies. The evolution of patients was marked by the occurrence of complications in 68.7% (n=90) and death in 85.5% (n=112) of patients. Complications were hepatic encephalopathy, gastrointestinal bleeding and infection of the ascites fluid in 52.67% (n=69), 14.50% (n=19) and 1.53% (n=2), respectively.
Conclusion :
HCC is a common cause of hospitalization. Diagnosis is late and the prognosis is serious. The main etiology is hepatitis B virus infection. Adequate management of HCC includes vaccination against this virus and monitoring of chronic liver disease.
References
1. Forner A, Reig M, Bruix J. Hepatocellular 121B carcinoma. Lancet. 2018 Mar 31;391(10127):1301-1314.
2. Chedid MF, Kruel CRP, Pinto MA, 122B Grezzana-Filho TJM, Leipnitz I, Kruel CDP et al. Hepatocellular Carcinoma: diagnosis and operative management. Arq Bras Cir Dig. 2017 Oct-Dec;30(4):272-278.
3. Bray F, Laversanne M, Sung H, Ferlay J, 123B Siegel RL, Soerjomataram I et al. Statistiques mondiales sur le cancer 2022: estimations GLOBOCAN de l’incidence et de la mortalité dans le monde pour 36 cancers dans 185 pays. CA Cancer J Clin. 2024 mai-juin ; 74(3):229-263.
4. Rumgay H, Arnold M, Ferlay J, Lesi O, 124B Cabasag CJ, Vignat J et al. Fardeau mondial du cancer primitif du foie en 2020 et prévisions jusqu’en 2040. J Hepatol. Décembre 2022 ; 77(6):1598-1606.
5. Ren Z, Ma X, Duan Z, Chen X. Diagnosis, 125B Therapy, and Prognosis for Hepatocellular Carcinoma. Anal Cell Pathol (Amst). 2020 Feb 3;2020:8157406. doi: 10.1155/2020/8157406.
6. Chidambaranathan-Reghupaty S, Fisher 126B PB, Sarkar D. Carcinome hépatocellulaire (CHC) : épidémiologie, étiologie et classification moléculaire. Adv Cancer Res. 2021;149:1-61.
7. Russo FP, Zanetto A, Pinto E, Battistella S, 127B Penzo B, Burra P, Farinati F. Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand? Int J Mol Sci. 2022 Jan 2;23(1):500. doi: 10.3390/ijms23010500.
8. Huang DQ, Mathurin P, Cortez-Pinto H, 128B Loomba R. Global epidemiology of alcoholassociated cirrhosis and HCC: trends, projections and risk factors. Nat Rev Gastroenterol Hepatol. 2023 Jan;20(1):37-49.
9. Shah PA, Patil R, Harrison SA. NAFLD129B related hepatocellular carcinoma: The growing challenge. Hepatology. 2023 Jan 1;77(1):323-338.
10. Galle PR, Dufour JF, Peck-Radosavljevic M, 130B Trojan J, Vogel A. Systemic therapy of advanced hepatocellular carcinoma. Future Oncol. 2021 Apr;17(10):1237-1251.
11. Kedar Mukthinuthalapati VVP, Sewram V, 131B Ndlovu N, Kimani S, Abdelaziz AO, Chiao EY et al. Hepatocellular Carcinoma in SubSaharan Africa. JCO Glob Oncol. 2021 May; 7:756-766.
12. Hamidine I, Garba AA, Elh Lamine HZ, 132B Mainou M, Seydou Midou AR, Haladou A. Morbidité et mortalité dans le service d’hépato-gastroentérologie de l’Hôpital National de Zinder au Niger. Rev int sc méd Abj - ISSN 1817-5503 - RISM 2022;24,3:245-
13. Semela D, Heim M. Carcinome 133B hépatocellulaire: dépistage, diagnostic et traitement. InForum Med Suisse 2008 (Vol. 8, No. 22, pp. 404-408).
14. Llovet JM, Brú C, Bruix J. Prognosis of 134B hepatocellular carcinoma: the BCLC staging classification. In Seminars in liver disease 1999 (Vol. 19, No. 03, pp. 329-338)
15. Sombié R. Un drame africain: à quand la fin 135B du carcinome hépatocellulaire? J Afri d'Hépato-Gastroentérol. 2017;11:1-2.
16. Diallo I, Ndiaye B, Touré M, Sow A, 136B Mbengue A, Diawara PS et al. Hepatocellular carcinoma in Senegal: epidemiological, clinical and etiological aspects about 229 cases at Hôpital Principal de Dakar. Pan African Medical Journal. 2021 Jan 28;38(1).
17. Yang JD, Mohamed EA, Aziz AO, Shousha 137B HI, Hashem MB, Nabeel MM et al. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. The lancet Gastroenterology & hepatology. 2017 Feb 1;2(2):103-11.
18. Jaquet A, Tchounga B, Tanon A, Bagny A, 138B Ekouevi DK, Traore HA, Sasco AJ, Maiga M, Dabis F. Etiology of hepatocellular carcinoma in West Africa, a case-control study. Int J Cancer. 2018 Aug 15;143(4):869-877.
19. Ladep NG, Lesi OA, Mark P, Lemoine M, 139B Onyekwere C, Afihene M, Crossey MM, Taylor-Robinson SD. Problem of hepatocellular carcinoma in West Africa. World J Hepatol. 2014 Nov 27;6(11):783-92.
20. Ndow G, Vo-Quang E, Shimakawa Y, 140B Ceesay A, Tamba S, Njai HF et al. Clinical characteristics and outcomes of patients with cirrhosis and hepatocellular carcinoma in The Gambia, west Africa: a prospective cohort study. Lancet Glob Health. 2023 Sep;11(9):e1383-e1392
21. Kondé A, Sidibé L, Fofana Y, Mallé O, Katilé 141B D, Samaké D et al. Epidemiological aspects of hepatocellular carcinoma at the Sominé Dolo hospital in Mopti. Health Sciences Diseases. 2022 Oct 29;23(11).
22. Guindo H, Maiga A, Dao K, Coulibaly A, 142B Dollo I, Guindo I et al. Aspects épidémiocliniques et étiologiques du Carcinome Hépatocellulaire à Gao. HEALTH SCIENCES AND DISEASE. 2024 May 24;25(6).
23. Gnangnon FH, Kpossou AR, Koffi NT, 143B Amidou SA, Zossou V, Toume C et al. Survie et facteurs pronostiques du cancer primitif du foie à Cotonou (République du Bénin) de 2014 à 2020. MTSI. 2024 Jul 18;4(3).
24. Peyrin-Biroulet L, Barraud H, Petit-Laurent 144B F, Ancel D, Watelet J, Chone L et al. Hépatotoxicité de la phytothérapie: données cliniques, biologiques, histologiques et mécanismes en cause pour quelques exemples caractéristiques. Gastroentérologie clinique et biologique. 2004 Jun 1;28(6-7):540-50.
Metrics
Downloads
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 I Hamidine, M Doutchi, F Ousseini, M Amadou Magagi, A Garba, M Mainou, N Moussa Habou, H Elh Lamine, B Mahamadou, H Abdou, H Adamou